[{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"6e8c9a27-8d9d-4402-a88d-164afbf13bc7","acronym":"FUS-ALS","url":"https://clinicaltrials.gov/study/NCT04768972","created_at":"2021-02-24T13:59:58.686Z","updated_at":"2024-07-02T16:34:59.891Z","phase":"Phase 3","brief_title":"FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)","source_id_and_acronym":"NCT04768972 - FUS-ALS","lead_sponsor":"Ionis Pharmaceuticals, Inc.","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/14/2021","start_date":" 06/14/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-05-31"},{"id":"d9dd8a9e-c9dc-461e-aece-5bc7f49d536e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709680","created_at":"2021-11-09T18:05:08.609Z","updated_at":"2024-07-02T16:35:02.132Z","phase":"Phase 1/2","brief_title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","source_id_and_acronym":"NCT03709680","lead_sponsor":"Pfizer","biomarkers":" EWSR1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2024-05-22"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"4357c08d-f1ac-4094-b621-ae0bea0ee724","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446416","created_at":"2021-01-18T21:23:50.447Z","updated_at":"2024-07-02T16:35:37.927Z","phase":"","brief_title":"Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients","source_id_and_acronym":"NCT04446416","lead_sponsor":"NaviFUS Corporation","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 08/04/2023","study_completion_date":" 08/04/2023","last_update_posted":"2023-09-06"},{"id":"8eaae7f3-8fd7-473d-b79f-cf1fc7507a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04988750","created_at":"2021-08-03T18:53:09.797Z","updated_at":"2024-07-02T16:35:38.011Z","phase":"","brief_title":"Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients","source_id_and_acronym":"NCT04988750","lead_sponsor":"NaviFUS Corporation","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-09-06"},{"id":"12cec976-855e-463e-8b34-da7323e7eb25","acronym":"BRAINFUL","url":"https://clinicaltrials.gov/study/NCT04940507","created_at":"2021-06-25T22:54:19.299Z","updated_at":"2024-07-02T16:35:41.831Z","phase":"","brief_title":"BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial","source_id_and_acronym":"NCT04940507 - BRAINFUL","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • FUS","pipe":"","alterations":" ","tags":["BRAF • FUS"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 06/10/2024","primary_completion_date":" 06/10/2024","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2023-07-27"},{"id":"2eee3991-cdd2-46bf-8242-9a9230dc239a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661852","created_at":"2021-01-19T20:43:03.275Z","updated_at":"2024-07-02T16:35:55.515Z","phase":"Phase 1","brief_title":"Cabozantinib With Topotecan-Cyclophosphamide","source_id_and_acronym":"NCT04661852","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EWSR1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • cyclophosphamide • Cometriq (cabozantinib capsule) • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/23/2020","start_date":" 12/23/2020","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2023-02-15"},{"id":"310e631e-b071-40b1-a519-01d9a5329dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129151","created_at":"2021-01-18T20:10:20.167Z","updated_at":"2024-07-02T16:35:55.610Z","phase":"Phase 2","brief_title":"Palbociclib + Ganitumab In Ewing Sarcoma","source_id_and_acronym":"NCT04129151","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDK4 • EWSR1 • IGF1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["CDK4 • EWSR1 • IGF1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ganitumab (AMG 479)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-14"},{"id":"ffec66bd-f196-4737-9890-d0bdeebbb38d","acronym":"Sonic ALA","url":"https://clinicaltrials.gov/study/NCT04845919","created_at":"2021-04-15T12:53:03.098Z","updated_at":"2024-07-02T16:35:57.491Z","phase":"Phase 2","brief_title":"Sonodynamic Therapy With ExAblate System in Glioblastoma Patients","source_id_and_acronym":"NCT04845919 - Sonic ALA","lead_sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-01-18"},{"id":"84ed0b0e-8803-431d-ace0-acaa07a9bb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT04804709","created_at":"2021-03-18T11:52:18.385Z","updated_at":"2024-07-02T16:36:17.149Z","phase":"Phase 1","brief_title":"Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)","source_id_and_acronym":"NCT04804709","lead_sponsor":"Cheng-Chia (Fred) Wu","biomarkers":" FUS","pipe":"","alterations":" ","tags":["FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Farydak (panobinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-02-14"},{"id":"f29597ba-4e28-4f5a-818d-718195cbece0","acronym":"MEGAN","url":"https://clinicaltrials.gov/study/NCT02856867","created_at":"2021-01-18T14:01:23.154Z","updated_at":"2024-07-02T16:37:22.707Z","phase":"Phase 2","brief_title":"Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)","source_id_and_acronym":"NCT02856867 - MEGAN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" HER-2 • FGFR2 • FUS","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • FGFR2 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • nintedanib • leucovorin calcium"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":"","study_completion_date":"","last_update_posted":"2017-05-09"}]